DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2017/0009296A1 Glessner Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2017/0009296A1 Glessner Et Al US 20170009296A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0009296A1 Glessner et al. (43) Pub. Date: Jan. 12, 2017 (54) ASSOCIATION OF RARE RECURRENT (60) Provisional application No. 61/376.498, filed on Aug. GENETIC VARATIONS TO 24, 2010, provisional application No. 61/466,657, ATTENTION-DEFICIT, HYPERACTIVITY filed on Mar. 23, 2011. DISORDER (ADHD) AND METHODS OF USE THEREOF FOR THE DAGNOSS AND TREATMENT OF THE SAME Publication Classification (71) Applicant: The Children's Hospital of Philadelphia, Philadelphia, PA (US) (51) Int. Cl. CI2O I/68 (2006.01) (72) Inventors: Joseph Glessner, Mullica Hill, NJ A63L/454 (2006.01) (US); Josephine Elia, Penllyn, PA (52) U.S. Cl. (US); Hakon Hakonarson, Malvern, CPC ........... CI2O I/6883 (2013.01); A61 K3I/454 PA (US) (2013.01); C12O 2600/156 (2013.01); C12O (21) Appl. No.: 15/063,482 2600/16 (2013.01) (22) Filed: Mar. 7, 2016 Related U.S. Application Data (57) ABSTRACT (63) Continuation of application No. 13/776,662, filed on Feb. 25, 2013, now abandoned, which is a continu ation-in-part of application No. PCT/US 11/48993, Compositions and methods for the detection and treatment filed on Aug. 24, 2011. of ADHD are provided. Patent Application Publication Jan. 12, 2017. Sheet 1 of 18 US 2017/000929.6 A1 Figure 1A ADHD Cases and Parentsi Siblings O SO Samples8 O 1. 1. 250C 40 gE 520 - Samples 3. Figure 1B Patent Application Publication Jan. 12, 2017. Sheet 2 of 18 US 2017/000929.6 A1 S&s sess'. ; S&s' ' Ny erre 8 Y-8 W - - 8 - - - - 8 - W - 8-8- W - 8 w w W & . ss --------SS is . 3.xx s S. tes. s v aas - ste. SS3, SSS 3. - - - ge (xxs wa. M& « » - - - -s &&. sš- or... & ss.S. Š. & & s. s: S- -: s: S- & SSS. SSS W SNS six&is-S ves Šs -$$$$$. 3.: . r S. Š es. & . $ . .- s & & ES & & & wx 8-. 3. & : --& Patent Application Publication Jan. 12, 2017. Sheet 3 of 18 US 2017/000929.6 A1 E8 is Sis: Seieigs 3.333i SáF 3Fs eiteit : '88. &&&. &"& & . &. .& 8.8 : & & 3,3 -->< : & C I s:ce....:::::::: ... sexes asses . 8& 2 a.a.a.a.a.a.s. is 88s is: 8 is . ; (.333 c is $.33&s, it: 8: sks: aii: -;&is :: *- : : - - is: a 3 x -: & S382. Seieist: 333i is a sixt: 33.3 -- ... '.... s. -: a ---...-3. sists 333338. Siskiiaietig: -x--x-x-x-x 3 - x -x-x-x-xx-x- 3. : 8.8 “*** 8. “””””. 3. ... e. xxx x. ... 8: & -: i: ... : : -; 3 & i. : 8 - 3 c. 3.33. Sigis sistic -3. --~ -3.s 3~x. -3.3 --~~ - --------------------------------------------- . is . x ; : & 3 & & 33 3: 3 x 3 & 8 x is 3 & S. : : 3 & Figure 3A Patent Application Publication Jan. 12, 2017. Sheet 4 of 18 US 2017/000929.6 A1 33.338AF AFF Exptistic: 38: 8A: SR: Seieigs 8-8-8-8-8 is . s. ‘. * : ... i. e. Y.: 33333333i: Beieist: -- E. : - 3 3: ... is: . is . a 's 3.3384 ERR is. Existics s 3. 3. g3333333333333333333. & exist scies: 3.x::::::::::: "...six: i::::::::::::::: Figure 3B Patent Application Publication Jan. 12, 2017. Sheet 5 of 18 US 2017/000929.6 A1 i&S BAFE.88 eletios a2S3, SRS es: 3 r or x * x-row 8 x 3 gr:rx or x < x < r < or & ... -------------------------- & -3. s sea nexa exa --& es. ess Sess -sk m N s s 83 s Ms s s & : sts 3. sy 3. s s s: cy Sa a.3. s s e & s 8. 3.838 (8 as: 882 esti . six r:x is x-x-x- 88 . ....r. s 3.3 x. xio x a 3, ... g. 3) is a g. g. g. -; S: , S: , S: -; Ya -.' s : a 2x R. is a x-xx-xx8. 3. & 88.8s It gig. Y. S. S. gr. 3 Y - as Sa: S - - - - - as is & W x 8.X. a Y is a six w S3R GR2 Rees Figure 3C Patent Application Publication Jan. 12, 2017. Sheet 6 of 18 US 2017/000929.6 A1 308A88AF R5 feetit iá832 BAF festigiication 3 xx-x-xx 3 xx-x-x-xx-» « xx 3.8 : 83 . : & ix. &&..... &......&. 8. .3 ...&-&. -a, - s -A -á - - s xs x x: x: ex x s: s : . 33 s 1n x: s 2 8: Exs & s s & s st s s 3:..................&e.......h.......: a........; & 23432 SAF festigiication: & & . &-x-xx & Figure 3D Patent Application Publication Jan. 12, 2017. Sheet 8 of 18 US 2017/000929.6 A1 SF-85S 8AF SG 8 teetion SF894 BAF jSp34 eietiot . ........................ x.............:... 8.......... a 3.88 x8.xx & x8x8.& . C 3 a. s. s. s. s. c. c. c. x. is a r. ss X r. ss. is is . ; : : -; e. e. e. e. A is a vs. o S: xx to -x s - & y & : SE8394. RR tisp23 Beietion SF 83.838&P sii/si tiglication Figure 3F Patent Application Publication Jan. 12, 2017. Sheet 9 of 18 US 2017/000929.6 A1 ...& 8: w s 88s. 88: 8888. Patent Application Publication Jan. 12, 2017. Sheet 10 of 18 US 2017/000929.6 A1 (C. 8. Population Pir s iple Components Ana ysiss MAGE Peregen Popu Principle Components Analys S. Figures Patent Application Publication Jan. 12, 2017. Sheet 12 of 18 US 2017/000929.6 A1 suya . s c k K as ? Patent Application Publication Jan. 12, 2017. Sheet 13 of 18 US 2017/000929.6 A1 OPCR independent Val Q SS Cis ebesoneuºgoea??ere», %) Figure 7 Patent Application Publication Jan. 12, 2017. Sheet 14 of 18 US 2017/000929.6 A1 denneNºdoo)Hoa ***~*~~~~~~~~****$3&&-&&#.~~$&&&~~~~-…-…--;*&&&+&&z&&&&&&&&&&&&&&********************? is $s. Patent Application Publication Jan. 12, 2017. Sheet 16 of 18 US 2017/0009296A1 Patent Application Publication Jan. 12, 2017. Sheet 17 of 18 US 2017/000929.6 A1 S. ?? s-XXSSax Patent Application Publication Jan. 12, 2017. Sheet 18 of 18 US 2017/000929.6 A1 & S$8 S&S:&sis S&SSSSSSSSSS &S&SS&S&S &S&S &S& S&SSSSSSSS& SSSSS& &S&S &SSSSSSSSS S&S&S &SSSSSSSSSSS S. &S&S& & &SSSSSSSSS 3& S&SSSSSSSSS& S& Figure 2. US 2017/000929.6 A1 Jan. 12, 2017 ASSOCATION OF RARE RECURRENT diagnosis and provide avenues for the development of GENETIC VARATIONS TO therapeutic agents having efficacy for the treatment of ATTENTION-DEFICIT, HYPERACTIVITY ADHD. DISORDER (ADHD) AND METHODS OF USE THEREOF FOR THE DAGNOSIS AND SUMMARY OF THE INVENTION TREATMENT OF THE SAME 0006. In accordance with the present invention, methods 0001. This application is a continuation of U.S. applica are provided for the diagnosis and treatment of ADHD. An tion Ser. No. 13/776,662 filed Feb. 25, 2013, which is a exemplary method entails detecting the presence of at least continuation in part of PCT/US2011/048993 filed Aug. 24, one CNV in a target polynucleotide wherein if said CNV(s) 2011 which in turn claims priority to U.S. Provisional is/are present, said patient has an increased risk for devel Applications 61/376.498 and 61/466,657 filed Aug. 24, 2010 oping ADHD. and Mar. 23, 2011 respectively, the entire contents of each 0007. In one aspect of the present invention, a method for being incorporated by reference as though set forth in full. detecting a propensity for developing attention deficit hyper activity disorder (ADHD) in a patient in need thereof is provided. An exemplary method entails detecting the pres FIELD OF THE INVENTION ence of at least 1, 2, 3, 4, 5, 6, 10, 20, 30 or all of the SNP 0002 This invention relates to the fields of genetics and containing nucleic acid in a target polynucleotide, said SNP the diagnosis of attention deficit hyperactivity disorder being informative of the presence of an ADHD associated (ADHD). More specifically, the invention provides compo copy number variation (CNV), wherein if said SNP is sitions and methods useful for the diagnosis and treatment of present, said patient has an increased risk for developing ADHD. ADHD, wherein said SNP containing nucleic acid is pro vided in Table 13. 0008. In another embodiment of the invention a method BACKGROUND OF THE INVENTION for identifying agents which alter neuronal signaling and/or 0003. Several publications and patent documents are morphology is provided. Such a method comprises provid cited through the specification in order to describe the state ing cells expressing at least one nucleic acid comprising the of the art to which this invention pertains. Each of these ADHD associated CNVs of the invention, (step a); provid citations is incorporated herein by reference as though set ing cells which express the cognate wild type sequences forth in full. which lack the CNV (step b); contacting the cells from each sample with a test agent and analyzing whether said agent 0004 Attention Deficit Hyperactivity Disorder (ADHD) alters neuronal signaling and/or morphology of cells of step is a common neuropsychiatric disorder with heritability a) relative to those of step b), thereby identifying agents estimates ranging from 30 to 90% (Derks, et al. 2008; Wood, which alter neuronal signaling and morphology. In a pre et al. 2008; Haberstic, et al. 2008). Most neurodevelopmen ferred embodiment the test agent modulates metabotropic tal disorders have been resistant to the genome wide asso glutamate receptor (mGluR) gene activity. In another ciation (GWA) approach, although recent progress has been embodiment the test agent is selected from a group consist made in autism (Glessner, et al. 2009: Derks, et al. 2008: ing of an mGluR positive allosteric modulators (PAM) (e.g., Wod, et al. 2008; Haberstic, et al. 2008: Wang, et al. 2009). mGluR5 PAM, mGluR7 PAM), an mGluR negative allos GWA studies have been reported in ADHD utilizing a cohort teric modulator (NAM) (e.g., mGluR2/3 NAM), and a of 958 parent-child trios recruited through the International tachykinin-3/neurokinin-3 receptor (TAC3/NK3R) antago Multicentre ADHD Genetics (IMAGE) study.
Load more

Recommended publications
  • (Arc/Arg3.1) in the Nucleus Accumbens Is Critical for the Acqui
    Behavioural Brain Research 223 (2011) 182–191 Contents lists available at ScienceDirect Behavioural Brain Research j ournal homepage: www.elsevier.com/locate/bbr Research report Expression of activity-regulated cytoskeleton-associated protein (Arc/Arg3.1) in the nucleus accumbens is critical for the acquisition, expression and reinstatement of morphine-induced conditioned place preference ∗ Xiu-Fang Lv, Ya Xu, Ji-Sheng Han, Cai-Lian Cui Neuroscience Research Institute and Department of Neurobiology, Peking University Health Science Center, Key Laboratory of Neuroscience, the Ministry of Education and Ministry of Public Health, 38 Xueyuan Road, Beijing 100191, PR China a r t i c l e i n f o a b s t r a c t Article history: Activity-regulated cytoskeleton-associated protein (Arc), also known as activity-regulated gene 3.1 Received 27 January 2011 (Arg3.1), is an immediate early gene whose mRNA is selectively targeted to recently activated synaptic Received in revised form 1 April 2011 sites, where it is translated and enriched. This unique feature suggests a role for Arc/Arg3.1 in coupling Accepted 18 April 2011 synaptic activity to protein synthesis, leading to synaptic plasticity. Although the Arc/Arg3.1 gene has been shown to be induced by a variety of abused drugs and its protein has been implicated in diverse Key words: forms of long-term memory, relatively little is known about its role in drug-induced reward memory. In Activity regulated cytoskeleton-associated this study, we investigated the potential role of Arc/Arg3.1 protein expression in reward-related associa- protein/activity-regulated gene (Arc/Arg3.1) tive learning and memory using morphine-induced conditioned place preference (CPP) in rats.
    [Show full text]
  • Synapse Development Organized by Neuronal Activity-Regulated Immediate- Early Genes Seungjoon Kim1, Hyeonho Kim1 and Ji Won Um1
    Kim et al. Experimental & Molecular Medicine (2018) 50:11 DOI 10.1038/s12276-018-0025-1 Experimental & Molecular Medicine REVIEW ARTICLE Open Access Synapse development organized by neuronal activity-regulated immediate- early genes Seungjoon Kim1, Hyeonho Kim1 and Ji Won Um1 Abstract Classical studies have shown that neuronal immediate-early genes (IEGs) play important roles in synaptic processes critical for key brain functions. IEGs are transiently activated and rapidly upregulated in discrete neurons in response to a wide variety of cellular stimuli, and they are uniquely involved in various aspects of synapse development. In this review, we summarize recent studies of a subset of neuronal IEGs in regulating synapse formation, transmission, and plasticity. We also discuss how the dysregulation of neuronal IEGs is associated with the onset of various brain disorders and pinpoint key outstanding questions that should be addressed in this field. Introduction experience-dependent synaptic changes and maturation Numerous studies have shown that neural activity plays of neural circuits. an important role in regulating synaptic strength, neuro- More than dozens of neuronal IEGs were identified by fi 1– 12 1234567890():,; 1234567890():,; nal membrane properties, and neural circuit re nement Paul Worley, Elly Nedivi, and colleagues , owing to the 3. In particular, sensory experiences continually influence use of the subtractive hybridization method, in combi- brain development at synaptic, circuit, and organismal nation with various neural stimulation protocols, most levels, as Hubel4 and Wiesel5 elegantly demonstrated in notably seizure paradigms. Among them, cAMP- their work on visual cortex organization during the cri- responsive element-binding protein (CREB) has been tical period5.
    [Show full text]
  • Podocin Inactivation in Mature Kidneys Causes Focal Segmental Glomerulosclerosis and Nephrotic Syndrome
    BASIC RESEARCH www.jasn.org Podocin Inactivation in Mature Kidneys Causes Focal Segmental Glomerulosclerosis and Nephrotic Syndrome Ge´raldine Mollet,*† Julien Ratelade,*† Olivia Boyer,*†‡ Andrea Onetti Muda,*§ ʈ Ludivine Morisset,*† Tiphaine Aguirre Lavin,*† David Kitzis,*† Margaret J. Dallman, ʈ Laurence Bugeon, Norbert Hubner,¶ Marie-Claire Gubler,*† Corinne Antignac,*†** and Ernie L. Esquivel*† *INSERM, U574, Hoˆpital Necker-Enfants Malades, Paris, France; †Faculte´deMe´ decine Rene´ Descartes, Universite´ Paris Descartes, Paris, France; ‡Pediatric Nephrology Department and **Department of Genetics, Hoˆpital Necker- Enfants Malades, Assistance Publique-Hoˆpitaux de Paris, Paris, France; §Department of Pathology, Campus ʈ Biomedico University, Rome, Italy; Department of Biological Sciences, Imperial College London, London, England; and ¶Max-Delbruck Center for Molecular Medicine, Berlin, Germany ABSTRACT Podocin is a critical component of the glomerular slit diaphragm, and genetic mutations lead to both familial and sporadic forms of steroid-resistant nephrotic syndrome. In mice, constitutive absence of podocin leads to rapidly progressive renal disease characterized by mesangiolysis and/or mesangial sclerosis and nephrotic syndrome. Using established Cre-loxP technology, we inactivated podocin in the adult mouse kidney in a podocyte-specific manner. Progressive loss of podocin in the glomerulus recapitu- lated albuminuria, hypercholesterolemia, hypertension, and renal failure seen in nephrotic syndrome in humans. Lesions of FSGS appeared
    [Show full text]
  • Homer1 Promotes Dendritic Spine Growth Through Ankyrin-G and Its Loss Reshapes the Synaptic Proteome
    Molecular Psychiatry (2021) 26:1775–1789 https://doi.org/10.1038/s41380-020-00991-1 ARTICLE Homer1 promotes dendritic spine growth through ankyrin-G and its loss reshapes the synaptic proteome 1 1 2 1,5 2 Sehyoun Yoon ● Nicolas H. Piguel ● Natalia Khalatyan ● Leonardo E. Dionisio ● Jeffrey N. Savas ● Peter Penzes 1,3,4 Received: 22 February 2020 / Revised: 24 November 2020 / Accepted: 7 December 2020 / Published online: 4 January 2021 © The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature 2021. This article is published with open access Abstract Homer1 is a synaptic scaffold protein that regulates glutamatergic synapses and spine morphogenesis. HOMER1 knockout (KO) mice show behavioral abnormalities related to psychiatric disorders, and HOMER1 has been associated with psychiatric disorders such as addiction, autism disorder (ASD), schizophrenia (SZ), and depression. However, the mechanisms by which it promotes spine stability and its global function in maintaining the synaptic proteome has not yet been fully investigated. Here, we used computational approaches to identify global functions for proteins containing the Homer1-interacting PPXXF motif within the postsynaptic compartment. Ankyrin-G was one of the most topologically important nodes in the postsynaptic peripheral 1234567890();,: 1234567890();,: membrane subnetwork, and we show that one of the PPXXF motifs, present in the postsynaptically-enriched 190 kDa isoform of ankyrin-G (ankyrin-G 190), is recognized by the EVH1 domain of Homer1. We use proximity ligation combined with super- resolution microscopy to map the interaction of ankyrin-G and Homer1 to distinct nanodomains within the spine head and correlate them with spine head size.
    [Show full text]
  • Downregulation of Carnitine Acyl-Carnitine Translocase by Mirnas
    Page 1 of 288 Diabetes 1 Downregulation of Carnitine acyl-carnitine translocase by miRNAs 132 and 212 amplifies glucose-stimulated insulin secretion Mufaddal S. Soni1, Mary E. Rabaglia1, Sushant Bhatnagar1, Jin Shang2, Olga Ilkayeva3, Randall Mynatt4, Yun-Ping Zhou2, Eric E. Schadt6, Nancy A.Thornberry2, Deborah M. Muoio5, Mark P. Keller1 and Alan D. Attie1 From the 1Department of Biochemistry, University of Wisconsin, Madison, Wisconsin; 2Department of Metabolic Disorders-Diabetes, Merck Research Laboratories, Rahway, New Jersey; 3Sarah W. Stedman Nutrition and Metabolism Center, Duke Institute of Molecular Physiology, 5Departments of Medicine and Pharmacology and Cancer Biology, Durham, North Carolina. 4Pennington Biomedical Research Center, Louisiana State University system, Baton Rouge, Louisiana; 6Institute for Genomics and Multiscale Biology, Mount Sinai School of Medicine, New York, New York. Corresponding author Alan D. Attie, 543A Biochemistry Addition, 433 Babcock Drive, Department of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, (608) 262-1372 (Ph), (608) 263-9608 (fax), [email protected]. Running Title: Fatty acyl-carnitines enhance insulin secretion Abstract word count: 163 Main text Word count: 3960 Number of tables: 0 Number of figures: 5 Diabetes Publish Ahead of Print, published online June 26, 2014 Diabetes Page 2 of 288 2 ABSTRACT We previously demonstrated that micro-RNAs 132 and 212 are differentially upregulated in response to obesity in two mouse strains that differ in their susceptibility to obesity-induced diabetes. Here we show the overexpression of micro-RNAs 132 and 212 enhances insulin secretion (IS) in response to glucose and other secretagogues including non-fuel stimuli. We determined that carnitine acyl-carnitine translocase (CACT, Slc25a20) is a direct target of these miRNAs.
    [Show full text]
  • Association of Common Genetic Variants of HOMER1 Gene with Levodopa Adverse Effects in Parkinson’S Disease Patients
    The Pharmacogenomics Journal (2014) 14, 289–294 & 2014 Macmillan Publishers Limited All rights reserved 1470-269X/14 www.nature.com/tpj ORIGINAL ARTICLE Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson’s disease patients AF Schumacher-Schuh1,2, V Altmann1, M Rieck1, L Tovo-Rodrigues1, TL Monte2, SM Callegari-Jacques3, MS Medeiros2, CRM Rieder2 and MH Hutz1 Levodopa is the most effective symptomatic therapy for Parkinson’s disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and visual hallucinations. HOMER1 is a protein with pivotal function in glutamate transmission, which has been related to the pathogenesis of these complications. This study investigates whether polymorphisms in the HOMER1 gene promoter region are associated with the occurrence of the chronic complications of levodopa therapy. A total of 205 patients with idiopathic Parkinson’s disease were investigated. Patients were genotyped for rs4704559, rs10942891 and rs4704560 by allelic discrimination with Taqman assays. The rs4704559 G allele was associated with a lower prevalence of dyskinesia (prevalence ratio (PR) ¼ 0.615, 95% confidence interval (CI) 0.426–0.887, P ¼ 0.009) and visual hallucinations (PR ¼ 0.515, 95% CI 0.295–0.899, P ¼ 0.020). Our data suggest that HOMER1 rs4704559 G allele has a protective role for the development of levodopa adverse effects. The Pharmacogenomics Journal (2014) 14, 289–294; doi:10.1038/tpj.2013.37; published online 15 October 2013 Keywords: dyskinesia; homer1; levodopa; Parkinson’s disease; pharmacogenetics; visual hallucinations. INTRODUCTION HOMER1 encodes a postsynaptic density protein highly expressed Idiopathic Parkinson’s disease (PD) affects 1–3% of people older in the brain.
    [Show full text]
  • The DLGAP Family: Neuronal Expression, Function and Role in Brain Disorders Andreas H
    Rasmussen et al. Molecular Brain (2017) 10:43 DOI 10.1186/s13041-017-0324-9 REVIEW Open Access The DLGAP family: neuronal expression, function and role in brain disorders Andreas H. Rasmussen1, Hanne B. Rasmussen2 and Asli Silahtaroglu1* Abstract The neurotransmitter glutamate facilitates neuronal signalling at excitatory synapses. Glutamate is released from the presynaptic membrane into the synaptic cleft. Across the synaptic cleft glutamate binds to both ion channels and metabotropic glutamate receptors at the postsynapse, which expedite downstream signalling in the neuron. The postsynaptic density, a highly specialized matrix, which is attached to the postsynaptic membrane, controls this downstream signalling. The postsynaptic density also resets the synapse after each synaptic firing. It is composed of numerous proteins including a family of Discs large associated protein 1, 2, 3 and 4 (DLGAP1-4) that act as scaffold proteins in the postsynaptic density. They link the glutamate receptors in the postsynaptic membrane to other glutamate receptors, to signalling proteins and to components of the cytoskeleton. With the central localisation in the postsynapse, the DLGAP family seems to play a vital role in synaptic scaling by regulating the turnover of both ionotropic and metabotropic glutamate receptors in response to synaptic activity. DLGAP family has been directly linked to a variety of psychological and neurological disorders. In this review we focus on the direct and indirect role of DLGAP family on schizophrenia as well as other brain diseases. Keywords: DLGAP1, DLGAP2, DLGAP3, DLGAP4, SAPAP, PSD, GKAP, Schizophrenia, Scaffold proteins, Synaptic scaling Introduction interaction partners, DLGAP1–4 proteins are likely to play The postsynaptic density (PSD) is a highly specialized a role in multiple processes of the PSD.
    [Show full text]
  • Imbalances in Prefrontal Cortex CC-Homer1 Versus CC-Homer2 Expression Promote Cocaine Preference
    The Journal of Neuroscience, May 8, 2013 • 33(19):8101–8113 • 8101 Behavioral/Cognitive Imbalances in Prefrontal Cortex CC-Homer1 versus CC-Homer2 Expression Promote Cocaine Preference Alexis W. Ary,1 Kevin D. Lominac,1 Melissa G. Wroten,1 Amy R. Williams,1 Rianne R. Campbell,1 Osnat Ben-Shahar,1 Georg von Jonquieres,2 Matthias Klugmann,2 and Karen K. Szumlinski1 1Department of Psychological and Brain Sciences and the Neuroscience Research Institute, University of California at Santa Barbara, Santa Barbara, California 93106-9660, and 2Translational Neuroscience Facility, School of Medical Sciences, University of New South Wales, Sydney, New South Wales 2052, Australia Homer postsynaptic scaffolding proteins regulate forebrain glutamate transmission and thus, are likely molecular candidates mediating hypofrontality in addiction. Protracted withdrawal from cocaine experience increases the relative expression of Homer2 versus Homer1 isoforms within medial prefrontal cortex (mPFC). Thus, this study used virus-mediated gene transfer strategies to investigate the functional relevance of an imbalance in mPFC Homer1/2 expression as it relates to various measures of sensorimotor, cognitive, emotional and motivational processing, as well as accompanying alterations in extracellular glutamate in C57BL/6J mice. mPFC Homer2b overexpression elevated basal glutamate content and blunted cocaine-induced glutamate release within the mPFC, whereas Homer2b knockdown produced the opposite effects. Despite altering mPFC glutamate, Homer2b knockdown failed to influence cocaine-elicited conditioned place preferences, nor did it produce consistent effects on any other behavioral measures. In contrast, elevating the relative expression of Homer2b versus Homer1 within mPFC, by overexpressing Homer2b or knocking down Homer1c, shifted the dose-response function for cocaine-conditioned reward to the left, without affecting cocaine locomotion or sensitization.
    [Show full text]
  • HOMER3 Facilitates Growth Factor-Mediated Β-Catenin Tyrosine
    Liu et al. J Hematol Oncol (2021) 14:6 https://doi.org/10.1186/s13045-020-01021-x RESEARCH Open Access HOMER3 facilitates growth factor-mediated β-Catenin tyrosine phosphorylation and activation to promote metastasis in triple negative breast cancer Qinghua Liu1,2†, Lixin He1†, Siqi Li1,3†, Fengyan Li4, Guangzheng Deng3, Xinjian Huang1,3, Muwen Yang1, Yunyun Xiao1, Xiangfu Chen1, Ying Ouyang1, Jinxin Chen1, Xuxia Wu1, Xi Wang1,3, Libing Song1 and Chuyong Lin1* Abstract Background: HOMER family scafolding proteins (HOMER1-3) play critical roles in the development and progression of human disease by regulating the assembly of signal transduction complexes in response to extrinsic stimuli. How- ever, the role of HOMER protein in breast cancer remains unclear. Methods: HOMER3 expression was examined by immunohistochemistry in breast cancer patient specimens, and its signifcance in prognosis was assessed by Kaplan–Meier survival analysis. The efects of HOMER3 in growth factor- induced β-Catenin activation were analyzed by assays such as TOP/FOP fash reporter, tyrosine phosphorylation assay and reciprocal immunoprecipitation (IP) assay. Role of HOMER3 in breast cancer metastasis was determined by cell function assays and mice tumor models. Results: Herein, we fnd that, among the three HOMER proteins, HOMER3 is selectively overexpressed in the most aggressive triple negative breast cancer (TNBC) subtype, and signifcantly correlates with earlier tumor metastasis and shorter patient survival. Mechanismly, HOMER3 interacts with both c-Src and β-Catenin, thus providing a scafolding platform to facilitate c-Src-induced β-Catenin tyrosine phosphorylation under growth factor stimulation. HOMER3 promotes β-Catenin nuclear translocation and activation, and this axis is clinically relevant.
    [Show full text]
  • Sven Loebrich and Elly Nedivi Physiol Rev 89:1079-1103, 2009
    Sven Loebrich and Elly Nedivi Physiol Rev 89:1079-1103, 2009. doi:10.1152/physrev.00013.2009 You might find this additional information useful... This article cites 293 articles, 112 of which you can access free at: http://physrev.physiology.org/cgi/content/full/89/4/1079#BIBL Medline items on this article's topics can be found at http://highwire.stanford.edu/lists/artbytopic.dtl on the following topics: Physiology .. Synaptic Transmission Physiology .. Neuronal Activity Oncology .. Transcriptional Regulation Medicine .. Genes Updated information and services including high-resolution figures, can be found at: http://physrev.physiology.org/cgi/content/full/89/4/1079 Additional material and information about Physiological Reviews can be found at: http://www.the-aps.org/publications/prv Downloaded from This information is current as of September 30, 2009 . physrev.physiology.org on September 30, 2009 Physiological Reviews provides state of the art coverage of timely issues in the physiological and biomedical sciences. It is published quarterly in January, April, July, and October by the American Physiological Society, 9650 Rockville Pike, Bethesda MD 20814-3991. Copyright © 2005 by the American Physiological Society. ISSN: 0031-9333, ESSN: 1522-1210. Visit our website at http://www.the-aps.org/. Physiol Rev 89: 1079–1103, 2009; doi:10.1152/physrev.00013.2009. The Function of Activity-Regulated Genes in the Nervous System SVEN LOEBRICH AND ELLY NEDIVI The Picower Institute for Learning and Memory, Departments of Brain and Cognitive Sciences and of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts I. Introduction 1079 II. Transcriptional Activation of Immediate Early Genes in the Nervous System 1080 III.
    [Show full text]
  • Transcriptomics Uncovers Substantial Variability Associated with Alterations in Manufacturing Processes of Macrophage Cell Therapy Products Olga L
    www.nature.com/scientificreports OPEN Transcriptomics uncovers substantial variability associated with alterations in manufacturing processes of macrophage cell therapy products Olga L. Gurvich1,3, Katja A. Puttonen1,3, Aubrey Bailey1, Anssi Kailaanmäki1, Vita Skirdenko1, Minna Sivonen1, Sanna Pietikäinen1, Nigel R. Parker2, Seppo Ylä‑Herttuala2 & Tuija Kekarainen1* Gene expression plasticity is central for macrophages’ timely responses to cues from the microenvironment permitting phenotypic adaptation from pro‑infammatory (M1) to wound healing and tissue‑regenerative (M2, with several subclasses). Regulatory macrophages are a distinct macrophage type, possessing immunoregulatory, anti‑infammatory, and angiogenic properties. Due to these features, regulatory macrophages are considered as a potential cell therapy product to treat clinical conditions, e.g., non‑healing diabetic foot ulcers. In this study we characterized two diferently manufactured clinically relevant regulatory macrophages, programmable cells of monocytic origin and comparator macrophages (M1, M2a and M0) using fow‑cytometry, RT‑qPCR, phagocytosis and secretome measurements, and RNA‑Seq. We demonstrate that conventional phenotyping had a limited potential to discriminate diferent types of macrophages which was ameliorated when global transcriptome characterization by RNA‑Seq was employed. Using this approach we confrmed that macrophage manufacturing processes can result in a highly reproducible cell phenotype. At the same time, minor changes introduced in manufacturing
    [Show full text]
  • A Novel Environment-Evoked Transcriptional Signature Predicts Reactivity in Single Dentate Granule Neurons
    ARTICLE DOI: 10.1038/s41467-018-05418-8 OPEN A novel environment-evoked transcriptional signature predicts reactivity in single dentate granule neurons Baptiste N. Jaeger 1,2, Sara B. Linker1, Sarah L. Parylak1, Jerika J. Barron 1, Iryna S. Gallina1, Christian D. Saavedra1, Conor Fitzpatrick1, Christina K. Lim1, Simon T. Schafer1, Benjamin Lacar1, Sebastian Jessberger2 & Fred H. Gage 1 1234567890():,; Activity-induced remodeling of neuronal circuits is critical for memory formation. This pro- cess relies in part on transcription, but neither the rate of activity nor baseline transcription is equal across neuronal cell types. In this study, we isolated mouse hippocampal populations with different activity levels and used single nucleus RNA-seq to compare their transcrip- tional responses to activation. One hour after novel environment exposure, sparsely active dentate granule (DG) neurons had a much stronger transcriptional response compared to more highly active CA1 pyramidal cells and vasoactive intestinal polypeptide (VIP) inter- neurons. Activity continued to impact transcription in DG neurons up to 5 h, with increased heterogeneity. By re-exposing the mice to the same environment, we identified a unique transcriptional signature that selects DG neurons for reactivation upon re-exposure to the same environment. These results link transcriptional heterogeneity to functional hetero- geneity and identify a transcriptional correlate of memory encoding in individual DG neurons. 1 The Salk Institute for Biological Studies, La Jolla, CA 92037-1002, USA. 2 Laboratory of Neural Plasticity, Faculty of Medicine and Science, Brain Research Institute, University of Zurich, 8057 Zurich, Switzerland. These authors contributed equally: Baptiste N. Jaeger, Sara B. Linker, Sarah L.
    [Show full text]